nach oben

International Journal of Hematology

Erschienen in:

16.02.2017 | Review Article

How we treat chronic active Epstein–Barr virus infection

verfasst von: Akihisa Sawada, Masami Inoue, Keisei Kawa

Erschienen in: International Journal of Hematology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Chronic active Epstein–Barr virus infection (CAEBV) is a prototype of the EBV-associated T- or NK-cell lymphoproliferative diseases, which also include hypersensitivity to mosquito bites and severe-type hydroavacciniforme. The manifestations of CAEBV are often self-limiting with minimum supportive care or only prednisolone and cyclosporine A with or without etoposide. However, allogeneic hematopoietic stem cell transplantation (HSCT) is the only cure, without which patients with CAEBV die within several years. A severe hypercytokinemia and hemophagocytic syndrome, which may occur suddenly, often results in a fatal clinical course. At out institute, we have established a 3-step strategy, including allogeneic HSCT, for the treatment of CAEBV. Seventy-nine patients with CAEBV and related diseases have been treated to date. The 3-year overall survival rate (3y-OS) is currently 87.3 ± 4.2% after planned allogeneic HSCT. However, 3y-OS in patients with uncontrolled active disease is only 16.7 ± 10.8%. To maximize survival rates with minimized late sequelae, we recommend earlier initiation and completion of the 3-step treatment without watchful waiting. We present six illustrative and difficult cases (including severe hypercytokinemia or emergent HSCT) and discuss them together with 73 residual cases.

Rickinson AB. Chronic, symptomatic Epstein–Barr virus infections. Immunol Today. 1986;7(1):13–4.CrossRefPubMed

Kikuta H, Taguchi Y, Tomizawa K, Kojima K, Kawamura N, Ishizaka A, et al. Epstein–Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature. 1988;333(6172):455–7.CrossRefPubMed

Jones JF, Shurin S, Abramowsky C, Kojima K, Kawamura N, Ishizaka A, et al. T-cell lymphomas containing Epstein–Barr viral DNA in patients with chronic Epstein–Barr virus infections. N Engl J Med. 1988;318(12):733–41.CrossRefPubMed

Ishihara S, Tawa A, Yumura-Yagi K, Murata M, Hara J, Yabuuchi H, et al. Clonal T-cell lymphoproliferation containing Epstein–Barr (EB) virus DNA in a patient with chronic active EB virus infection. Jpn J Cancer Res. 1989;80(2):99–101.CrossRefPubMed

Kawa-Ha K, Ishihara S, Ninomiya T, Yumura-Yagi K, Hara J, Murayama F, et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein–Barr viral DNA. J Clin Invest. 1989;84(1):51–5.CrossRefPubMedPubMedCentral

Okano M, Kawa K, Kimura H, Yachie A, Wakiguchi H, Maeda A, et al. Proposed guidelines for diagnosing chronic active Epstein–Barr virus infection. Am J Hematol. 2005;80(1):64–9.CrossRefPubMed

Ishihara S, Ohshima K, Tokura Y, Yabuta R, Imaishi H, Wakiguchi H, et al. Hypersensitivity to mosquito bites conceals clonal lymphoproliferation of Epstein–Barr viral DNA-positive natural killer cells. Jpn J Cancer Res. 1997;88(1):82–7.CrossRefPubMed

Ishihara S, Okada S, Wakiguchi H, Kurashige T, Hirai K, Kawa-Ha K. Clonal lymphoproliferation following chronic active Epstein–Barr virus infection and hypersensitivity to mosquito bites. Am J Hematol. 1997;54(4):276–81.CrossRefPubMed

Kawa K, Okamura T, Yagi K, Takeuchi M, Nakayama M, Inoue M. Mosquito allergy and Epstein–Barr virus-associated T/natural killer-cell lymphoproliferative disease. Blood. 2001;98(10):3173–4.CrossRefPubMed

10.

Hirai Y, Yamamoto T, Kimura H, Ito Y, Tsuji K, Miyake T, et al. Hydroa vacciniforme is associated with increased numbers of Epstein–Barr virus-infected γδT cells. J Invest Dermatol. 2012;132(5):1401–8.CrossRefPubMed

11.

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.CrossRefPubMed

12.

Kawa K. Epstein–Barr virus-associated diseases in humans. Int J Hematol. 2000;71(2):108–17.PubMed

13.

Kawa K. Diagnosis and treatment of Epstein–Barr virus-associated natural killer cell lymphoproliferative disease. Int J Hematol. 2003;78(1):24–31.CrossRefPubMed

14.

Sawada A, Inoue M, Koyama-Sato M, Kondo O, Yamada K, Shimizu M, et al. Umbilical cord blood as an alternative source of reduced-intensity hematopoietic stem cell transplantation for chronic Epstein–Barr virus-associated T or natural killer cell lymphoproliferative diseases. Biol Blood Marrow Transplant. 2014;20(2):214–21.CrossRefPubMed

15.

Kawa K, Ishihara S, Okamura T, Inoue M. Chronic active Epstein–Barr virus infection and lymphoproliferative diseases. Gann Monograph Cancer Res. 1998;45:139–47.

16.

Okamura T, Hatsukawa Y, Arai H, Inoue M, Kawa K. Blood stem-cell transplantation for chronic active Epstein–Barr virus with lymphoproliferation. Lancet. 2000;356(9225):223–224.

17.

Okamura T, Kishimoto T, Inoue M, Honda M, Yamashita N, Wakiguchi H, et al. Unrelated bone marrow transplantation for Epstein–Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant. 2003;31(2):105–11.CrossRefPubMed

18.

Kawa K, Sawada A, Sato M, Okamura T, Sakata N, Kondo O, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant. 2011;46(1):77–83.CrossRefPubMed

19.

Yasui N, Kato M, Mori M, Akiyama K, Seki M, Takahashi H, et al. A case of chronic active Epstein–Barr virus infection presenting a fatal couse of tumor lysis syndrome. Jpn J Pediatr Hematol Oncol. 2013;50(2):253–257.

20.

Takeuchi M, Yanagimachi M, Yanai T, Sasaki K, Kato H, Yokosuka T, et al. Two cases of severe mosquito bite allergy that progressed to chronic active Epstein–Barr virus infection. J Jpn Pediatr Soc. 2014;118(5):1578–80.

21.

Tawfik K, Liron Y, Ayman AR, Schneider R, Wolf DG, Ronen L. A heart breaking case of rapidly developing severe hemophagocytic syndrome secondary to chronic active EBV infection; a case report and review of the literature. J Clin Virol. 2015;67:14–16. Review.

22.

Kimura H, Kawa K, Oh-ishi T, Maeda A, Okamura T, Ohga S, et al. Long-term prognosis of chronic active Epstein–Barr virus infection. J Jpn Pediatr Soc. 2006;110(11):1578–80.

23.

Arai A, Imadome K, Watanabe Y, Yoshimori M, Koyama T, Kawaguchi T, et al. Clinical features of adult-onset chronic active Epstein–Barr virus infection: a retrospective analysis. Int J Hematol. 2011;93(5):602–9.CrossRefPubMed

24.

Ishihara S, Okada S, Wakiguchi H, Kurashige T, Morishima T, Kawa-Ha K. Chronic active Epstein–Barr virus infection in children in Japan. Acta Paediatr. 1995;84(11):1271–5.CrossRefPubMed

25.

Koyama M, Takeshita Y, Sakata A, Sawada A, Yasui M, Okamura T, et al. Cytotoxic chemotherapy successfully induces durable complete remission in 2 patients with mosquito allergy resulting from Epstein–Barr virus-associated T-/natural killer cell lymphoproliferative disease. Int J Hematol. 2005;82(5):437–40.CrossRefPubMed

26.

Koyama M, Higuchi B, Kim JY, Sato E, Sawada A, Yasui M, et al. The efficacy of immunochemotherapy for chronic active Epstein–Barr virus infection. Hematol Oncol. 2004;49(4):415–416.

27.

Shimizu M, Sawada A, Yamada K, Kondo O, Koyama-Sato M, Shimizu S, et al. Encouraging results of preserving ovarian function after allo-HSCT with RIC. Bone Marrow Transplant. 2012;47(1):141–2.CrossRefPubMed

28.

Arai A, Sakashita C, Hirose C, Imadome KI, Yamamoto M, Jinta M, et al. Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: efficacy and predictive markers. Bone Marrow Transplant. 2016;51(6):879–82.CrossRefPubMed

29.

Schluns KS, Kieper WC, Jameson SC, Lefrançois L. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol. 2000;1(5):426–32.CrossRefPubMed

30.

Sawada A, Shimizu M, Isaka K, Higuchi K, Mayumi A, Yoshimoto Y, et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies. Pediatr Hematol Oncol. 2014;31(8):754–64.CrossRefPubMed

31.

Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410–4416.

32.

Jung KS, Cho SH, Kim SJ, Ko YH, Kang ES, Kim WS.L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia. J Hematol Oncol. 2016;18(9):41–44.

33.

Huang Y, de Reyniès A, de Leval L, Ghazi B, Martin-Garcia N, Travert M, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood. 2010;115(6):1226–37.CrossRefPubMedPubMedCentral

34.

Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocyticlymphohistiocytosis in mice. Blood. 2016;128(1):60–71.CrossRefPubMed

35.

Kanazawa T, Hiramatsu Y, Iwata S, Siddiquey M, Sato Y, Suzuki M, et al. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Clin Cancer Res. 2014;20(19):5075–84.CrossRefPubMed

36.

Marsh RA, Allen CE, McClain KL, Weinstein JL, Kanter J, Skiles J, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101–9.CrossRefPubMed

37.

Lai J, Tan WJ, Too CT, Choo JA, Wong LH, Mustafa FB, et al. Targeting Epstein–Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities. Blood. 2016;128(10):1396–407.CrossRefPubMedPubMedCentral

38.

Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, et al. Autologous Epstein–Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;100(12):4059–66.CrossRefPubMed

39.

Wang Q, Liu H, Zhang X, Liu Q, Xing Y, Zhou X, et al. High doses of mother’s lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood. Blood. 2010;116(26):5941–7.CrossRefPubMed

Titel: How we treat chronic active Epstein–Barr virus infection
verfasst von: Akihisa Sawada
Masami Inoue
Keisei Kawa
Publikationsdatum: 16.02.2017
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 4/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-017-2192-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

How we treat chronic active Epstein–Barr virus infection

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Platelet count evolution as a predictor of outcome after splenectomy for immune thrombocytopenic purpura

BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma

Achievement of disease control with donor-derived EB virus-specific cytotoxic T cells after allogeneic peripheral blood stem cell transplantation for aggressive NK-cell leukemia

Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials

An atypical case of late-onset systemic lupus erythematosus with systemic lymphadenopathy and severe autoimmune thrombocytopenia/neutropenia mimicking malignant lymphoma

Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie